JP2015509512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509512A5 JP2015509512A5 JP2014560264A JP2014560264A JP2015509512A5 JP 2015509512 A5 JP2015509512 A5 JP 2015509512A5 JP 2014560264 A JP2014560264 A JP 2014560264A JP 2014560264 A JP2014560264 A JP 2014560264A JP 2015509512 A5 JP2015509512 A5 JP 2015509512A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- hal
- unsubstituted
- atoms
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- -1 2,3-dihydro-benzo [1,4] dioxinyl Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 241000222722 Leishmania <genus> Species 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 2
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 241000186367 Mycobacterium avium Species 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 8
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12001568 | 2012-03-07 | ||
| EP12001568.0 | 2012-03-07 | ||
| PCT/EP2013/000440 WO2013131609A1 (en) | 2012-03-07 | 2013-02-14 | Triazolopyrazine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509512A JP2015509512A (ja) | 2015-03-30 |
| JP2015509512A5 true JP2015509512A5 (OSRAM) | 2016-03-31 |
| JP6049768B2 JP6049768B2 (ja) | 2016-12-21 |
Family
ID=47715983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560264A Expired - Fee Related JP6049768B2 (ja) | 2012-03-07 | 2013-02-14 | トリアゾロピラジン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150051202A1 (OSRAM) |
| EP (1) | EP2822948B1 (OSRAM) |
| JP (1) | JP6049768B2 (OSRAM) |
| CN (1) | CN104159901B (OSRAM) |
| AR (1) | AR090240A1 (OSRAM) |
| AU (1) | AU2013230286B2 (OSRAM) |
| CA (1) | CA2866450C (OSRAM) |
| ES (1) | ES2579981T3 (OSRAM) |
| HK (1) | HK1203948A1 (OSRAM) |
| IL (1) | IL234466A (OSRAM) |
| TW (1) | TW201341384A (OSRAM) |
| WO (1) | WO2013131609A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015017011A (es) * | 2013-06-10 | 2016-04-25 | Bayer Pharma AG | Compuestos nuevos para el tratamiento del cancer. |
| TWI674263B (zh) * | 2013-12-19 | 2019-10-11 | 瑞士商諾華公司 | 用於治療寄生蟲疾病之化合物及組合物 |
| TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
| PT3105226T (pt) | 2014-02-13 | 2019-11-06 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| ME03654B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) * | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| RU2719446C2 (ru) * | 2014-11-03 | 2020-04-17 | Айомет Фарма Лтд | Фармацевтическое соединение |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
| EP3498693B1 (en) * | 2016-08-10 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| PL3559009T3 (pl) | 2016-12-22 | 2021-10-25 | Calithera Biosciences, Inc. | Kompozycje i sposoby hamowania aktywności arginazy |
| IL312674A (en) * | 2018-01-29 | 2024-07-01 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| EP3746075B1 (en) * | 2018-01-29 | 2025-09-03 | Merck Patent GmbH | Gcn2 inhibitors and uses thereof |
| AU2019297361B2 (en) * | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| MX2022002720A (es) * | 2019-09-05 | 2022-08-10 | Lunan Pharmaceutical Group Corp | Inhibidor de magl, procedimiento de preparacion y uso del mismo. |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| EP4359415A1 (en) * | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN115819425A (zh) * | 2022-12-22 | 2023-03-21 | 五邑大学 | 一种三唑并六元氮杂环-2-胺类化合物及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| CA2531333A1 (en) | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| US20090054358A1 (en) | 2004-07-19 | 2009-02-26 | The John Hopkins University | Flt3 inhibitors for immune suppression |
| WO2006075023A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| CN101454326A (zh) * | 2006-05-31 | 2009-06-10 | 加拉帕戈斯股份有限公司 | 用于治疗变性和炎性疾病的三唑并吡嗪化合物 |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| BRPI1009637A2 (pt) * | 2009-06-05 | 2019-04-30 | Cephalon, Inc | composto, composição e uso de um composto |
| PH12012501381A1 (en) * | 2010-01-15 | 2012-10-22 | Janssen Pharmaceuticals Inc | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| EA201300282A1 (ru) * | 2010-08-27 | 2013-08-30 | Мерк Патент Гмбх | Производные триазолопиразина |
-
2013
- 2013-02-14 EP EP13704368.3A patent/EP2822948B1/en not_active Not-in-force
- 2013-02-14 US US14/382,678 patent/US20150051202A1/en not_active Abandoned
- 2013-02-14 WO PCT/EP2013/000440 patent/WO2013131609A1/en not_active Ceased
- 2013-02-14 ES ES13704368.3T patent/ES2579981T3/es active Active
- 2013-02-14 CN CN201380012661.XA patent/CN104159901B/zh not_active Expired - Fee Related
- 2013-02-14 HK HK15104522.2A patent/HK1203948A1/xx unknown
- 2013-02-14 JP JP2014560264A patent/JP6049768B2/ja not_active Expired - Fee Related
- 2013-02-14 CA CA2866450A patent/CA2866450C/en not_active Expired - Fee Related
- 2013-02-14 AU AU2013230286A patent/AU2013230286B2/en not_active Ceased
- 2013-03-05 AR ARP130100705A patent/AR090240A1/es unknown
- 2013-03-06 TW TW102107941A patent/TW201341384A/zh unknown
-
2014
- 2014-09-04 IL IL234466A patent/IL234466A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509512A5 (OSRAM) | ||
| JP2015524450A5 (OSRAM) | ||
| US20250019355A1 (en) | Compounds | |
| JP2015515961A5 (OSRAM) | ||
| WO2019166621A1 (en) | Phenylsulfonylurea derivatives useful as nlrp3 inhibitors | |
| TW202513571A (zh) | 吡啶并[4,3-d]嘧啶化合物 | |
| US20230241068A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| JP2015529229A5 (OSRAM) | ||
| JP2015508099A5 (OSRAM) | ||
| JP2015508086A5 (OSRAM) | ||
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP2015529657A5 (OSRAM) | ||
| CN104177363B (zh) | 双环杂环胺类Hedgehog信号通路抑制剂 | |
| JP2015508085A5 (OSRAM) | ||
| JP2015535831A5 (OSRAM) | ||
| CN106414451A (zh) | Mertk‑特异性吡咯并嘧啶化合物 | |
| JP2020097596A5 (OSRAM) | ||
| JP2011525502A5 (OSRAM) | ||
| CN109906224A (zh) | 三唑吡啶化合物及其应用 | |
| CN113508114B (zh) | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 | |
| BR112020019134A2 (pt) | produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos | |
| TW202012371A (zh) | 具乙烯碸部分之k-ras調節劑 | |
| CN108392478A (zh) | 穿心莲内酯类化合物在制备用于放射性损伤药物方面的应用 | |
| CN116887834A (zh) | 多环IRAK和flt3抑制化合物以及其用途 | |
| CN112313233A (zh) | Jak家族激酶的小分子抑制剂 |